NCT05223582View on ClinicalTrials.gov

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
High-risk Prostate CancerNeoadjuvant Therapy
Interventions
DRUG

Abiraterone acetate

Patients would be treated with 1000mg abiraterone qd.

DRUG

Fluzoparib

Patients would be treated with 150mg fluzoparib bid.

DRUG

Prednisone

Patients would be treated with 5mg prednisone bid.

DRUG

Androgen deprivation therapy

Patients would get medical castration.

PROCEDURE

Radical Prostatectomy

Patients would get radical prostatectomy after the neoadjuvant treatment.

Trial Locations (1)

200000

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER